Compare OXM & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OXM | PACB |
|---|---|---|
| Founded | 1942 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.9M | 555.5M |
| IPO Year | N/A | 2010 |
| Metric | OXM | PACB |
|---|---|---|
| Price | $36.86 | $2.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $44.80 | $2.08 |
| AVG Volume (30 Days) | 399.9K | ★ 8.0M |
| Earning Date | 12-10-2025 | 02-12-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,493,854,000.00 | $154,584,000.00 |
| Revenue This Year | N/A | $4.19 |
| Revenue Next Year | $1.54 | $12.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.57 | $0.85 |
| 52 Week High | $87.93 | $2.73 |
| Indicator | OXM | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 48.06 | 64.68 |
| Support Level | $37.18 | $2.09 |
| Resistance Level | $39.21 | $2.22 |
| Average True Range (ATR) | 2.38 | 0.20 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 32.56 | 82.58 |
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company generates majority of its revenue from the Tommy Bahama division.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.